What is it about?
My co-author and I shared insight into the research interaction of some medicinal plants targeting RBP4 in treating cardiometabolic diseases (CMD).
Featured Image
Why is it important?
It provides literature basis for researchers, who are interested in CMD drug design, to focus on medicinal plants that inhibit the secretion of serum RBP4 in the adipose tissue for therapeutic approach to CMD.
Read the Original
This page is a summary of: Targeting Retinol-Binding Protein 4 (RBP4) in the Management of Cardiometabolic Diseases, Cardiovascular Toxicology, August 2023, Springer Science + Business Media,
DOI: 10.1007/s12012-023-09803-8.
You can read the full text:
Contributors
The following have contributed to this page
